VRTX 8-K Current Reports

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Oct 20, 2026)

Vertex Pharmaceuticals Incorporated (VRTX) announced a significant addition to its Board of Directors on October 20, 2026, with the appointment of Daniel Brennan. This appointment increases the size of the Board from ten to eleven members. Mr. Brennan brings a wealth of financial expertise, having served as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation until his retirement in June 2025, and holding various senior finance roles there for many years prior. His extensive background in financial leadership is expected to be a valuable asset to Vertex's strategic and financial oversight. In addition to his extensive corporate finance experience, Mr. Brennan has a strong track record of public company board service, currently sitting on the boards of Waters Corporation and Madrigal Pharmaceuticals, and previously serving on Nuance Corporation's board. His appointment to the Audit and Finance Committee will further strengthen the board's financial governance. The company also disclosed that Mr. Brennan received a $400,000 restricted stock unit award upon joining, which is set to vest in October 2027, aligning his interests with long-term shareholder value.

Oct 20, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Sep 1, 2026)

Vertex Pharmaceuticals Incorporated announced a significant leadership transition in its finance department with the appointment of Jonathan Poole as Executive Vice President and Chief Financial Officer (CFO), effective January 1, 2027. Mr. Poole, a seasoned finance executive with prior CFO experience at Evelo Biosciences and Genocea Biosciences, and extensive background at Shire plc, will succeed Charles F. Wagner, Jr. Mr. Wagner will transition from his CFO responsibilities to focus solely on his role as Executive Vice President and Chief Operating Officer. This appointment brings a well-qualified executive into a critical financial leadership position within Vertex. Investors should note the details of Mr. Poole's compensation package, which includes a $750,000 base salary and a 90% target annual bonus. The agreements also outline severance provisions for termination without cause or resignation for good reason, including salary continuation and accelerated equity vesting, as well as change of control provisions designed to retain key talent during potential acquisition scenarios.

Sep 1, 2026 8-K

Material AgreementsRegulation FDOther Events+1

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 3, 2026)

Vertex Pharmaceuticals reported strong second quarter 2026 results, with total revenue up 12% year over year to $3.33 billion. Growth was led by cystic fibrosis (CF) franchise performance, particularly ALYFTREK, which generated $574 million in Q2 versus $157 million a year earlier, while TRIKAFTA/KAFTRIO declined to $2.50 billion from $2.55 billion. GAAP net income was $1.10 billion ($4.31 diluted EPS) and non-GAAP net income was $1.21 billion ($4.73 non-GAAP diluted EPS). Operating expenses rose on JOURNAVX launch investment and renal franchise build-out, and the GAAP effective tax rate increased to 21.0% from 19.5%. Cash and marketable securities reached $13.6 billion, up from $12.3 billion at year-end 2025, aided by operating cash flow and partly offset by share repurchases. management raised full-year 2026 total revenue guidance to $13.1–$13.2 billion from $12.95–$13.1 billion, while reiterating its expense and tax guidance. The guidance excludes the pending acquisition of Crinetics Pharmaceuticals, announced in July at $85.00 per share in cash for an equity value of roughly $10.0 billion (about $8.8 billion net of acquired cash), with closing expected in Q3 2026. That deal would add rare endocrine diseases as a fifth pillar, and management plans updated 2026 guidance after closing. Key near-term catalysts include the povetacicept IgAN PDUFA date of November 30, 2026, the AMPLIFIED Phase 2 inaxaplin data this fall, VX-828 and VX-670 data in the second half of 2026, and the Crinetics closing. Investors should note that the filing itself is a press release furnished under Item 2.02 and is not deemed filed for Section 18 purposes.

Aug 3, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Jul 7, 2026)

On July 6, 2026, Vertex Pharmaceuticals (VRTX) signed a definitive merger agreement to acquire Crinetics Pharmaceuticals (CRNX) for $85.00 per share in cash. The deal values Crinetics at about $10.0 billion in equity, or $8.8 billion net of cash. Both boards unanimously approved it. Crinetics will become a wholly owned Vertex subsidiary through a reverse triangular merger. Closing requires Crinetics stockholder approval, HSR clearance and any required foreign clearances, and is expected in Q3 2026. The deal is not subject to a financing condition. Strategically, Vertex is adding two late-stage endocrinology assets. PALSONIFY is an oral, once-daily treatment for acromegaly, approved by the FDA and EMA and launched in the U.S. in October 2025. Atumelnant, an oral ACTH receptor antagonist, is in pivotal development for congenital adrenal hyperplasia (CAH) and has Phase 2 data in ACTH-dependent Cushing's syndrome. Vertex says the two assets have roughly $5 billion or more in combined peak annual revenue potential. Management expects the deal to accelerate revenue growth, become accretive to non-GAAP operating income in 2029, and modestly affect 2026 revenue and non-GAAP operating expenses, with 2026 guidance to be updated at closing. The deal is funded with cash on hand and a $4.5 billion unsecured 364-day bridge facility from Bank of America, BofA Securities and Morgan Stanley Senior Funding, which is expected to be replaced by permanent financing. Investors should weigh the approximately $350.5 million termination fee payable by Crinetics in specified circumstances, the January 6, 2027 outside date, and the usual risks of pipeline and launch execution.

Jul 7, 2026 8-K

Leadership ChangesShareholder Matters

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (May 13, 2026)

Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on May 13, 2026, detailing the outcomes of its Annual Shareholder Meeting held on the same date. The most significant outcomes include the overwhelming approval of the 2026 Stock and Option Plan, replacing the previous 2013 plan, and the election of all ten nominated directors to the Board. These approvals indicate strong shareholder confidence in the company's leadership and its long-term incentive strategies. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent auditor and approved, on an advisory basis, the 2025 executive compensation program. While a shareholder proposal regarding the right to act by written consent received majority approval, the company's proposed 2026 Stock and Option Plan secured substantially higher levels of support, signaling a clear priority for management's compensation and equity-based incentive frameworks from the investor base.

May 13, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 4, 2026)

Vertex Pharmaceuticals reported first quarter 2026 results on May 4, 2026, with total revenue of $2.99 billion, up 8% year over year, driven by cystic fibrosis (CF) franchise performance and early contributions from CASGEVY and JOURNAVX. GAAP net income rose to $1.03 billion from $646 million, though the prior-year period carried a $379 million intangible impairment. Non-GAAP diluted EPS was $4.47 versus $4.06 a year earlier. CF product revenue was $2.92 billion, with ALYFTREK ($424 million, up from $54 million) increasingly offsetting a 7% decline in TRIKAFTA/KAFTRIO to $2.35 billion as the mix shifts to the newer product. Management reiterated full-year 2026 guidance of $12.95–13.1 billion in total revenue and at least $500 million in non-CF product revenue. Expenses rose modestly, with non-GAAP R&D, acquired IPR&D and SG&A at $1.29 billion versus $1.23 billion, reflecting JOURNAVX launch spending and build-out of the renal franchise led by povetacicept in IgA nephropathy. Cash and marketable securities reached $13.0 billion, up from $12.3 billion at year-end 2025, supported by operating cash flow and partly offset by share repurchases. The company completed the rolling BLA submission for povetacicept in IgAN under a Priority Review Voucher, which implies a six-month FDA review from acceptance, and it discontinued the VX-522 cystic fibrosis gene-editing program after persistent tolerability issues. For investors, the key questions are the durability of TRIKAFTA's decline against ALYFTREK's ramp, the pace of non-CF revenue growth needed to hit guidance, and regulatory timing for povetacicept and the CASGEVY pediatric submission. The filing is an Item 2.02 earnings release furnished under Exhibit 99.1, so its content is not subject to Section 18 liability.

May 4, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Apr 29, 2026)

Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K reporting a change in its Board of Directors. Suketu Upadhyay, a current director, has informed the Board of his decision not to stand for re-election at the upcoming 2026 annual meeting of shareholders. This decision stems from Mr. Upadhyay's recent appointment as the forthcoming Chief Financial Officer of Incyte Corporation, a role that presents scheduling conflicts with his board responsibilities at Vertex.

Apr 29, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Mar 31, 2026)

Vertex Pharmaceuticals Incorporated (VRTX) has announced a significant regulatory milestone with the completion of its rolling Biologics Licensing Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for povetacicept. This investigational therapy is being pursued for the treatment of immunoglobulin A nephropathy (IgAN) in adults, a condition with significant unmet medical need. The company has leveraged a priority review voucher, which is expected to expedite the FDA's review process. Vertex anticipates an accelerated six-month review timeline from the BLA acceptance date, compared to the standard ten months, potentially bringing this therapy to market sooner if approved.

Mar 31, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 12, 2026)

Vertex Pharmaceuticals reported strong fourth quarter and full year 2025 results, with full year total revenue of $12.0 billion, up 9% year over year, and fourth quarter revenue of $3.19 billion, up 10%. Growth was driven by cystic fibrosis (CF) franchise performance, including the newer ALYFTREK, along with early contributions from CASGEVY and JOURNAVX. GAAP net income for 2025 was $3.95 billion (GAAP diluted EPS $15.32) versus a GAAP net loss of $536 million in 2024, a swing largely attributable to $4.4 billion of acquired IPR&D from the 2024 Alpine Immune Sciences acquisition. Non-GAAP net income was $4.75 billion. Cash, cash equivalents and marketable securities ended the year at $12.3 billion. For 2026, Vertex guided to total revenue of $12.95 billion to $13.1 billion, including $500 million or more from non-CF products. Combined non-GAAP R&D, AIPR&D and SG&A expenses are expected at $5.65 billion to $5.75 billion, and the non-GAAP effective tax rate at 19.5% to 20.5%. Management highlighted several near-term catalysts, including the planned completion of the povetacicept BLA for IgA nephropathy in the first half of 2026 (with a priority review voucher potentially shortening review to six months) and multiple pediatric regulatory submissions. The quarter also included items that flatter the reported results and merit attention. The fourth quarter GAAP tax rate of 10.5% reflected a one-time benefit from previously deferred tax credits, and the full year 2025 results included a $379 million intangible asset impairment charge. Investors should weigh the strong top-line momentum against the pipeline's dependence on pending data readouts and regulatory decisions, as well as the dependence of the business on CF products, which still make up the large majority of revenue.

Feb 12, 2026 8-K

Earnings & ResultsLeadership ChangesExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Nov 3, 2025)

Vertex Pharmaceuticals reported third quarter 2025 results on November 3, 2025, with total revenue of $3.08 billion, up 11% year over year. U.S. revenue grew 15% to $1.98 billion, driven by continued cystic fibrosis (CF) demand including the newly launched ALYFTREK, early contributions from CASGEVY and JOURNAVX, and favorable CF net pricing. Outside the U.S., revenue rose 4% to $1.10 billion. GAAP net income was $1.08 billion ($4.20 diluted EPS) versus $1.05 billion a year earlier, and non-GAAP net income was $1.24 billion ($4.80 non-GAAP diluted EPS), up from $4.38. Cash and marketable securities totaled $12.0 billion at quarter end. Management refined full-year 2025 guidance. Total revenue is now expected at $11.9 to $12.0 billion, a narrowing at the low end from the prior $11.85 to $12.0 billion range. Combined GAAP R&D, acquired IPR&D and SG&A expenses were raised to $5.65 to $5.8 billion, and non-GAAP expenses to $5.0 to $5.1 billion, reflecting accelerated povetacicept programs and increased JOURNAVX sales and marketing investment. The non-GAAP tax rate guidance was cut sharply to 17% to 18% from 20.5% to 21.5%, due to one-time tax benefits, including Alpine-related R&D credits recognized in Q3 and previously deferred benefits expected in Q4. Investors should treat the tax benefit as non-recurring when judging underlying earnings quality. The filing also highlights pipeline progress, most notably full enrollment of the Phase 3 IgAN study of povetacicept, with the first module of the BLA on track for submission by year-end 2025 and the full submission planned for the first half of 2026. The filing also notes a $379 million intangible asset impairment charge recorded in the first nine months of 2025, and a temporary postponement of zimislecel dosing completion pending a manufacturing analysis. Both are relevant risk items for investors to monitor.

Nov 3, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 4, 2025)

Vertex Pharmaceuticals (VRTX) reported second quarter 2025 results on August 4, 2025, with total revenue of $2.96 billion, up 12% year over year. U.S. revenue rose 14% to $1.85 billion on strong demand and favorable gross-to-net, while ex-U.S. revenue grew 8% to $1.12 billion. GAAP net income was $1.03 billion ($3.99 diluted EPS) versus a $3.6 billion net loss a year earlier, which was driven by the non-cash $4.4 billion Alpine acquired IPR&D charge. Comparisons are therefore distorted, and the underlying trend is better judged on revenue growth and non-GAAP figures, with non-GAAP net income of $1.17 billion ($4.52 per diluted share). Cash and marketable securities reached $12.0 billion. Vertex reiterated full-year 2025 guidance, including revenue of $11.85 to $12.0 billion and non-GAAP effective tax rate of 20.5% to 21.5%. Growth is being driven by the cystic fibrosis franchise, where TRIKAFTA/KAFTRIO sales reached $2.55 billion, and by early contributions from three launches: ALYFTREK (CF, $157 million in the quarter), CASGEVY (sickle cell disease and beta thalassemia, $30 million), and JOURNAVX (non-opioid acute pain, $12 million). Management highlighted access gains for JOURNAVX, with coverage for nearly half of U.S. covered lives. The pipeline update included a discontinued monotherapy program (VX-993 in acute pain), a narrowed path in peripheral neuropathic pain, and reprioritized povetacicept indications, with a possible accelerated approval filing in IgAN in the first half of 2026. The filing also disclosed that Chief Scientific Officer David Altshuler will retire effective August 1, 2026, with Mark Bunnage, current SVP of Global Research, succeeding him effective February 1, 2026. This is a planned transition and not a disruption to guidance. Investors should watch launch uptake and reimbursement progress, the timing of pivotal readouts, and R&D spending levels in the second half of 2025.

Aug 4, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (May 19, 2025)

Vertex Pharmaceuticals Incorporated (VRTX) announced today a significant expansion of its capital return program with the authorization of a new $4.0 billion stock repurchase program, effective immediately. This new "2025 Repurchase Program" demonstrates management's confidence in the company's financial health and its commitment to enhancing shareholder value. The program has no expiration date and allows for flexibility in execution, including open market purchases and privately negotiated transactions, subject to market conditions and other strategic investment opportunities. This substantial new authorization complements the existing "2023 Repurchase Program," under which approximately $775 million remains available as of May 16, 2025. Combined, VRTX now has the authorization to repurchase up to $4.775 billion of its common stock. This aggressive buyback strategy signals a proactive approach to capital allocation, potentially reducing share count and increasing earnings per share over time, which should be viewed positively by investors.

May 19, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Shareholder Vote Results (May 14, 2025)

Vertex Pharmaceuticals Incorporated (VRTX) held its annual shareholder meeting on May 14, 2025, with the results of key votes detailed in this 8-K filing. The company's Board of Directors saw all eleven nominated members overwhelmingly re-elected, indicating strong shareholder confidence in the current leadership and governance. Furthermore, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by a significant majority of shareholders. Investors will also note the advisory approval of the 2024 executive compensation program. However, a shareholder proposal concerning 'excessive golden parachutes' was not approved, suggesting that current executive compensation structures, despite the advisory vote on the 2024 program, remain a point of contention or scrutiny for a portion of the shareholder base. Overall, the meeting reflects broad support for the company's direction and governance framework, with a minor exception regarding executive compensation policies.

May 14, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 5, 2025)

Vertex Pharmaceuticals reported first-quarter 2025 results with total revenue of $2.77 billion, up 3% year over year, driven by TRIKAFTA/KAFTRIO (about $2.54 billion) and an early contribution from the U.S. launch of ALYFTREK. U.S. revenue rose 9% to $1.66 billion on strong demand and higher net realized pricing, while ex-U.S. revenue fell 5% to $1.11 billion, largely due to the expected revenue decline in Russia, where Vertex cites intellectual property violations. The company raised the low end of its full-year 2025 total revenue guidance by $100 million to $11.85–$12.0 billion, and reiterated its GAAP and non-GAAP expense and non-GAAP tax rate guidance. Profitability was mixed. GAAP net income fell to $646 million (diluted EPS $2.49) from $1.1 billion a year earlier, reflecting a $379.0 million intangible asset impairment tied to VX-264 (the cells-plus-device type 1 diabetes program, now discontinued) and higher operating spend. Non-GAAP net income was $1.1 billion (diluted EPS $4.06), down from $1.2 billion. Combined R&D, acquired IPR&D and SG&A expenses rose on pipeline investment and JOURNAVX commercial launch costs. Cash and marketable securities were $11.4 billion at quarter end, up from $11.2 billion, despite ongoing share repurchases. The quarter's pipeline and launch news was substantial. JOURNAVX (suzetrigine), the non-opioid acute pain drug, has broad early uptake with roughly 94 million lives with covered access and a formal agreement with a large PBM. Povetacicept has completed enrollment of its IgAN interim cohort, with a potential U.S. accelerated approval filing in the first half of 2026, and has moved into pivotal development in primary membranous nephropathy. Zimislecel's Phase 3 dosing is expected to complete in Q2 2025, with filings planned for 2026. Investors should note that the company's guidance is reaffirmed in its essentially unchanged expense outlook, and that the VX-522 MAD study was paused for a tolerability issue.

May 5, 2025 8-K

Earnings & ResultsLeadership ChangesExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Mar 28, 2025)

Vertex Pharmaceuticals announced a significant update regarding its type 1 diabetes (T1D) program, specifically the VX-264 clinical trial. The company has decided not to advance VX-264 further in clinical development based on trial results. This decision necessitates an evaluation of intangible assets associated with the VX-264 program for impairment. Vertex currently anticipates a non-cash, intangible asset impairment charge of approximately $400 million. This charge will be recognized in GAAP operating expenses for the first quarter and the full year 2025. The company plans to provide detailed results of this impairment analysis in its upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2025. Investors should note that this charge is non-cash and impacts operating expenses, not cash flow directly in the current period.

Mar 28, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 10, 2025)

Vertex Pharmaceuticals (VRTX) reported fourth-quarter and full-year 2024 results on February 10, 2025. Full-year 2024 product revenue rose 12% to $11.02 billion, led by TRIKAFTA/KAFTRIO, with U.S. net product revenue up 11% to $6.68 billion and ex-U.S. revenue up 13% to $4.34 billion. However, GAAP results were sharply negative: a GAAP net loss of $(536) million (GAAP EPS of $(2.08)) reflected $4.6 billion of acquired IPR&D expense, mainly the roughly $4.4 billion associated with the Alpine Immune Sciences acquisition. Non-GAAP net income was $111 million ($0.42 per diluted share). Cash, cash equivalents and marketable securities fell to $11.2 billion from $13.7 billion, reflecting the Alpine cash consideration and share repurchases. management guided to FY2025 total revenue of $11.75 to $12.0 billion, with non-GAAP combined R&D, AIPR&D and SG&A expenses of $4.9 to $5.0 billion and a non-GAAP effective tax rate of 20.5% to 21.5%. Growth drivers include the U.S. launch of ALYFTREK (approved December 20, 2024, for ages 6+ with CF), the early launch of JOURNAVX (FDA-approved January 30, 2025, for moderate-to-severe acute pain), and continued CASGEVY uptake. The company also highlighted a broad late-stage pipeline, including pivotal programs in APOL1-mediated kidney disease, IgA nephropathy and type 1 diabetes. In a separate 8-K item, Vertex announced that Stuart Arbuckle, EVP and Chief Operating Officer, will retire effective July 1, 2025. CFO Charles (Charlie) Wagner, Jr. will add the COO role, and Duncan McKechnie, current SVP and head of North America Commercial, will become Chief Commercial Officer, both effective the same date. Wagner's new employment agreement sets a $1,000,000 base salary and a 100% target bonus, with defined severance and change-of-control protections.

Feb 10, 2025 8-K

Regulation FD

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Regulation FD Disclosure (Dec 20, 2024)

Vertex Pharmaceuticals announced a significant milestone with the U.S. Food and Drug Administration's approval of ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) on December 19, 2024. This new therapy targets cystic fibrosis (CF) in patients aged 6 and older who possess at least one F508del mutation or another responsive mutation in the CFTR gene. The approval represents a key advancement in Vertex's CF franchise and offers a new treatment option for a broad segment of the CF patient population. The company has also set the wholesale acquisition cost (WAC) for ALYFTREK in the United States at $370,269 annually, or $28,404 per 28-day pack. This pricing, while substantial, is typical for advanced therapies in the rare disease space and will be a crucial factor for payers and patients to consider. Investors will be closely watching market uptake and reimbursement dynamics for ALYFTREK as it launches.

Dec 20, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Nov 4, 2024)

Vertex Pharmaceuticals reported third quarter 2024 results on November 4, 2024, with product revenue of $2.77 billion, up 12% year over year, driven primarily by TRIKAFTA/KAFTRIO (up to $2.59 billion from $2.27 billion). U.S. product revenue grew 10% to $1.71 billion and ex-U.S. revenue grew 14% to $1.06 billion. The company raised its full-year 2024 product revenue guidance to $10.8–$10.9 billion from $10.65–$10.85 billion, while keeping its expense and acquired IPR&D guidance unchanged. GAAP net income was $1.0 billion ($4.01 diluted EPS) and non-GAAP net income was $1.1 billion ($4.38 diluted EPS), both roughly flat with Q3 2023 as higher R&D and SG&A spending offset revenue growth. Full-year 2024 results are heavily distorted by the $4.4 billion Alpine Immune Sciences acquisition-related IPR&D charge taken in Q2 2024, which drove nine-month GAAP net loss to $1.45 billion. Cash, cash equivalents and marketable securities fell to $11.2 billion from $13.7 billion at year-end 2023, reflecting the Alpine cash consideration and share repurchases. Investors should focus on the pipeline and launch catalysts: an FDA PDUFA date of January 2, 2025 for vanzacaftor triple in CF, and a PDUFA date of January 30, 2025 for suzetrigine in moderate-to-severe acute pain. Three programs (suzetrigine in DPN, povetacicept in IgAN, and VX-880 in T1D) advanced to Phase 3 during the quarter. The press release is furnished under Item 2.02 rather than filed, so its contents are not subject to Section 18 liability unless specifically incorporated by reference into another filing.

Nov 4, 2024 8-K

Material Agreements

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Aug 16, 2024)

Vertex Pharmaceuticals Incorporated (VRTX) has entered into material definitive agreements by amending its headquarters leases for approximately 1.1 million square feet of office and laboratory space in Boston, MA. The amendments extend the lease terms for the properties at 50 Northern Avenue and 11 Fan Pier Boulevard significantly, from the current expiration of December 2028 to June 30, 2044. This provides Vertex with long-term stability and a strategic operational base in a key biotech hub. This extension demonstrates a commitment to Vertex's current Boston headquarters and suggests confidence in its ongoing operations and future growth plans within this location. Investors can view this as a positive development, ensuring continuity and a stable environment for research, development, and administrative functions for at least the next two decades, with options for further extensions.

Aug 16, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 1, 2024)

Vertex Pharmaceuticals reported Q2 2024 results that were dominated by a one-time charge tied to its acquisition of Alpine Immune Sciences. Product revenue rose 6% year over year to $2.65 billion, led by TRIKAFTA/KAFTRIO, with U.S. net product revenue up 7% to $1.61 billion and ex-U.S. up 5% to $1.03 billion. However, Acquired IPR&D expense jumped to $4.4 billion (versus $111 million a year earlier), producing a GAAP net loss of $3.6 billion, or $(13.92) per diluted share, compared with net income of $916 million in Q2 2023. Non-GAAP net loss was $3.3 billion, or $(12.83) per share. Management raised full-year 2024 product revenue guidance to $10.65-$10.85 billion from $10.55-$10.75 billion. The company now expects combined GAAP R&D and SG&A of $5.0-$5.2 billion, and AIPR&D expense of about $4.6 billion, with a non-GAAP effective tax rate near 100% because the Alpine charge is non-deductible. Cash, equivalents and marketable securities fell to $10.2 billion from $13.7 billion, reflecting roughly $5.0 billion of cash paid for Alpine. The filing also highlights regulatory momentum. The FDA accepted the vanzacaftor triple NDA (PDUFA January 2, 2025) and suzetrigine NDA (PDUFA January 30, 2025), both with Priority Review. Investors should weigh the strong revenue trajectory and pipeline catalysts against the sharp near-term earnings and tax-rate distortion, and the reduced cash cushion, while recognizing that the AIPR&D charge is a non-cash-like accounting event tied to the Alpine deal.

Aug 1, 2024 8-K

Other EventsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Jun 27, 2024)

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on June 27, 2024, to provide an update on the accounting treatment and financial impact of its previously announced acquisition of Alpine Immune Sciences, Inc. The company expects to account for the acquisition as an asset acquisition, which will result in a significant one-time, non-deductible Acquired In-Process Research & Development (AIPR&D) expense of approximately $4.4 billion in the second quarter of 2024. This expense will impact both GAAP and non-GAAP reported operating expenses and net income, and will influence the company's financial guidance for the full year 2024. In addition to the AIPR&D charge, Vertex anticipates incurring approximately $200 million in transaction-related compensation expense due to the acceleration of unvested Alpine awards. This compensation expense will also affect reported GAAP operating expenses and net income for the current quarter and the full year. Despite these significant non-recurring charges, Vertex reaffirms its expectation to absorb Alpine's non-GAAP R&D and SG&A expenses within its previously provided operating expense guidance range for the remainder of 2024.

Jun 27, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (May 20, 2024)

On May 20, 2024, Vertex Pharmaceuticals (VRTX) completed its acquisition of Alpine Immune Sciences, Inc. (Alpine) for approximately $5.0 billion in equity value. The deal was executed under the Merger Agreement signed April 10, 2024, following a tender offer. Upon completion of the tender offer, Vertex's wholly owned subsidiary, Adams Merger Sub, Inc., merged with and into Alpine under Section 251(h) of the Delaware General Corporation Law. This allowed the merger to close without an Alpine stockholder meeting, with Alpine surviving as a wholly owned subsidiary of Vertex. The filing is largely a completion notice rather than a source of new financial results. Its main investor-relevant disclosure is that Vertex will finalize the accounting treatment for the acquisition during the second quarter of 2024, which means the purchase price allocation and related accounting conclusions remain pending in this filing. The filing also incorporates the full Merger Agreement by reference, with schedules omitted under Regulation S-K Item 601(b)(2). For investors, the key takeaways are the size of the transaction, the speed of execution from signing to closing (about six weeks), and the structure, which avoided a lengthy stockholder vote. The filing does not disclose the deal's strategic rationale, financing details, or the expected revenue or earnings impact, so those points would need to be sought in Vertex's earnings materials or other disclosures.

May 20, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Shareholder Vote Results (May 15, 2024)

Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K report on May 15, 2024, detailing the results of their Annual Meeting of Shareholders held on May 15, 2024. The key takeaway for investors is the overwhelming shareholder support for the company's current leadership and operational direction. All incumbent directors were re-elected with substantial 'For' votes, indicating strong confidence in their stewardship. Furthermore, shareholders ratified the appointment of Ernst & Young LLP as the independent auditor and approved, on an advisory basis, the executive compensation program. These results suggest alignment between management and shareholders on corporate governance and financial oversight. While the majority of proposals received significant shareholder approval, it is noteworthy that two shareholder proposals were put to a vote. One proposal regarding special shareholder meeting improvements was approved, while a proposal for a report on racial and gender pay gaps was not approved. These outcomes provide insight into shareholder priorities and areas where the company may need to address investor concerns moving forward.

May 15, 2024 8-K

Material AgreementsOther EventsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 6, 2024)

Vertex Pharmaceuticals reported first quarter 2024 results on May 6, 2024, with product revenue of $2.69 billion, up 13% year over year. U.S. net product revenue rose 8% to $1.52 billion and ex-U.S. revenue rose 21% to $1.17 billion, driven by TRIKAFTA/KAFTRIO uptake including younger patient label expansions. GAAP net income increased 57% to $1.10 billion ($4.21 diluted EPS) and non-GAAP net income rose 56% to $1.24 billion ($4.76 non-GAAP diluted EPS). Profit growth was supported by higher product revenue and lower acquired IPR&D expense, which fell from $347.1 million to $76.8 million. Cash, cash equivalents and marketable securities reached $14.6 billion, up from $13.7 billion at year-end 2023. Vertex reiterated full year 2024 guidance, including product revenue of $10.55 to $10.75 billion and combined non-GAAP R&D, acquired IPR&D and SG&A expenses of $4.3 to $4.4 billion. The company also highlighted regulatory progress: submissions for the vanzacaftor triple in cystic fibrosis to the FDA and EMA, a rolling NDA for suzetrigine in moderate-to-severe acute pain expected to complete in Q2 2024, and CASGEVY launches in several geographies. The announced acquisition of Alpine Immune Sciences for approximately $4.9 billion in cash, which adds povetacicept for IgA nephropathy, is expected to close in the second quarter of 2024. Investors should note that the press release's financial figures reflect a strong quarter, but the outlook depends on successful regulatory approvals, CASGEVY reimbursement and uptake, and the Alpine integration. The filing also notes that the Exhibit 99.1 press release is furnished rather than filed, so its content is not subject to Section 18 liability unless specifically incorporated into another filing.

May 6, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Apr 11, 2024)

Vertex Pharmaceuticals Inc. (VRTX) has announced a significant development through an 8-K filing on April 11, 2024, detailing a definitive merger agreement to acquire Alpine Immune Sciences, Inc. The acquisition will be conducted via a cash tender offer at $65.00 per share, valuing the transaction at approximately $65.00 per share, net to the seller in cash. This strategic move aims to bolster Vertex's pipeline, particularly in the realm of autoimmune and kidney diseases, aligning with its focus on developing innovative therapies for serious diseases. The transaction is not subject to a financing condition, indicating Vertex has secured the necessary capital. The deal is expected to close within approximately one year, pending customary closing conditions, including regulatory approvals and the successful tender of a majority of Alpine's outstanding shares. Key Alpine shareholders, collectively holding about 25.5% of the outstanding shares, have entered into tender and support agreements, indicating strong backing for the transaction.

Apr 11, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 5, 2024)

Vertex Pharmaceuticals (VRTX) reported fourth quarter and full-year 2023 results on February 5, 2024, filed under Item 2.02 with the press release attached as Exhibit 99.1. Full-year 2023 product revenue rose 11% to $9.87 billion, driven by TRIKAFTA/KAFTRIO in ex-U.S. markets and continued TRIKAFTA growth in the U.S., including the launch in children aged 2 to 5. U.S. product revenue grew 6% to $6.04 billion, while ex-U.S. revenue grew 18% to $3.83 billion. Full-year GAAP net income rose 9% to $3.62 billion, and non-GAAP net income rose 3% to $3.97 billion. Cash and marketable securities ended the year at $13.7 billion, up from $10.9 billion. Note that the balance sheet in the filing shows $11.2 billion of cash and marketable securities plus $2.5 billion of long-term marketable securities, which together account for the $13.7 billion figure. Management guided to 2024 product revenue of $10.55 to $10.75 billion, with non-GAAP R&D, acquired IPR&D and SG&A expenses of $4.3 to $4.4 billion and a non-GAAP effective tax rate of 20% to 21%. Combined GAAP expenses are guided to $4.9 to $5.1 billion, and the gap is mainly stock-based compensation. Combined expense growth in 2023 was elevated by acquired IPR&D, which rose to $527 million from $116 million. Fourth-quarter product revenue grew 9% to $2.52 billion, but GAAP operating income fell about 4% year over year to $988.5 million as R&D and SG&A costs rose. The main investor catalysts are regulatory and commercial. Vertex plans to file NDAs and related applications by mid-2024 for vanzacaftor/tezacaftor/deutivacaftor in CF and for VX-548 in acute pain. CASGEVY has been approved in the U.S., Great Britain, Bahrain and Saudi Arabia for sickle cell disease and transfusion-dependent beta thalassemia, and the company is working to secure reimbursement and expand treatment centers. Pipeline milestones include the inaxaplin Phase 3 start in APOL1-mediated kidney disease in Q1 2024, and VX-880 remains on a protocol-specified pause.

Feb 5, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Dec 8, 2023)

Vertex Pharmaceuticals Inc. (VRTX) announced a significant development on December 8, 2023, with the U.S. Food and Drug Administration (FDA) approval of CASGEVY™ (exagamglogene autotemcel). This groundbreaking therapy is an autologous, genome-edited hematopoietic stem cell-based gene therapy designed for the treatment of sickle cell disease (SCD) in patients aged 12 and older who experience recurrent vaso-occlusive crises. This approval marks a major milestone for Vertex and offers a potentially transformative treatment option for a patient population with high unmet medical needs.

Dec 8, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Dec 5, 2023)

Vertex Pharmaceuticals Incorporated announced a significant addition to its Board of Directors with the appointment of Nancy Thornberry, effective December 5, 2023. This appointment increases the size of the Board from ten to eleven members, indicating the company's strategic growth and the need for expanded oversight. Ms. Thornberry brings a wealth of experience from her extensive career in the biotechnology and pharmaceutical sectors, including her recent role as CEO of Kallyope, Inc., and significant leadership positions at Merck & Co., Inc. Her background in R&D and executive leadership is expected to provide valuable strategic guidance to Vertex. In addition to her operational expertise, Ms. Thornberry is an experienced board member, currently serving on the boards of Denali Therapeutics, Inc. and Schrödinger, Inc. Her compensation for joining the Vertex Board includes a substantial $400,000 restricted stock unit award, vesting in December 2024. This equity award aligns her interests with those of shareholders and underscores the company's commitment to attracting high-caliber talent to its leadership. Investors should view this as a positive development, signaling a strengthening of the company's governance and strategic capabilities.

Dec 5, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Nov 6, 2023)

Vertex Pharmaceuticals reported third quarter 2023 results on November 6, 2023, showing product revenue of $2.48 billion, up 6% year over year, with U.S. net product revenue up 7% to $1.55 billion and ex-U.S. up 6% to $929 million. GAAP net income rose 11% to $1.04 billion ($3.97 diluted EPS), while non-GAAP net income rose 2% to $1.06 billion ($4.08 non-GAAP diluted EPS). Growth was driven by TRIKAFTA/KAFTRIO, including the launch in children aged 2 to 5 in the U.S. and reimbursement gains abroad, though TRIKAFTA/KAFTRIO growth was partly offset by a 56% decline in other CF products, which fell to $209 million. Management raised full-year 2023 CF product revenue guidance to approximately $9.85 billion from $9.7 to $9.8 billion, and reiterated combined non-GAAP R&D, acquired IPR&D and SG&A expense guidance at $4.1 to $4.2 billion. Operating expenses rose sharply, with combined non-GAAP R&D, acquired IPR&D and SG&A up about 31% year over year to $993 million in the quarter, reflecting late-stage pipeline investment and launch preparation. The GAAP effective tax rate fell to 12.2% due to R&D tax credits, which included a $74 million discrete benefit. Cash, cash equivalents and marketable securities were $13.6 billion at quarter end. The key near-term catalysts are the December 8, 2023 PDUFA date for exa-cel in sickle cell disease following an FDA advisory committee meeting, completion of pivotal Phase 3 studies for vanzacaftor triple combination in CF and VX-548 in acute pain by year-end 2023 with data expected in early 2024, and Phase 2 VX-548 data in diabetic peripheral neuropathy in late 2023. Investors should note that the guidance and pipeline timelines are forward-looking and subject to regulatory and clinical risk.

Nov 6, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Oct 5, 2023)

Vertex Pharmaceuticals Inc. (VRTX) announced a significant change to its board of directors with the appointment of Michel Lagarde, effective October 5, 2023. Mr. Lagarde brings extensive experience from leadership roles at Thermo Fisher Scientific, including his current position as Executive Vice President and Chief Operating Officer. His background also includes experience in private equity within the healthcare sector, suggesting a valuable addition to Vertex's strategic oversight. This appointment increases the size of the Board from nine to ten members. Mr. Lagarde's compensation for joining the board includes a substantial $400,000 restricted stock unit award, which is scheduled to vest in October 2024. This signals a commitment to aligning director interests with shareholder value. The filing also confirms no related-party transactions or specific appointment understandings requiring further disclosure.

Oct 5, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 1, 2023)

Vertex Pharmaceuticals reported second quarter 2023 results on August 1, 2023, with product revenue of $2.49 billion, up 14% year over year, led by TRIKAFTA/KAFTRIO growth both in the U.S. (+7% to $1.51 billion) and internationally (+26% to $985 million). GAAP net income rose 13% to $915.7 million (diluted EPS $3.52), and non-GAAP net income rose 9% to $1.01 billion (non-GAAP diluted EPS $3.89). Cash, cash equivalents and marketable securities reached $12.6 billion at June 30, 2023, up from $10.9 billion at year-end 2022, supported by strong operating cash flow. Management raised full-year 2023 CF product revenue guidance to $9.7 to $9.8 billion from $9.55 to $9.7 billion, net of an approximately 150-basis-point foreign currency headwind. Combined non-GAAP R&D, acquired IPR&D and SG&A expense guidance was raised to $4.1 to $4.2 billion from $3.9 to $4.0 billion, driven partly by higher acquired IPR&D, including a $70 million milestone payment to CRISPR Therapeutics. The non-GAAP tax rate guidance was unchanged, and the company does not guide GAAP tax rate. The pipeline news was the main catalyst: FDA accepted the exa-cel BLAs for severe sickle cell disease (Priority Review, PDUFA date December 8, 2023) and transfusion-dependent beta thalassemia (PDUFA date March 30, 2024), with an FDA advisory committee planned. Vertex also expects completion of the SKYLINE and RIDGELINE vanzacaftor triple studies by year-end 2023 and VX-548 pivotal acute pain program results in late 2023 or early 2024. Investors should note that the advisory committee and the regulatory timelines are the key near-term risks to monitor.

Aug 1, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Shareholder Vote Results (May 18, 2023)

Vertex Pharmaceuticals Incorporated held its annual shareholder meeting on May 17, 2023, where key governance and executive matters were put to a vote. The meeting resulted in the overwhelming re-election of all nine nominated directors to the Board, with each director receiving substantial support. Shareholders also overwhelmingly ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2023, indicating strong confidence in the company's audit oversight. Furthermore, the advisory vote on the 2022 executive compensation program showed significant shareholder approval, though with a notable percentage of opposition. In line with shareholder preference, the Board has determined that future advisory votes on executive compensation will be held annually. This consistency in director elections and auditor ratification, coupled with a clear direction on executive compensation voting frequency, reflects a stable corporate governance framework for Vertex Pharmaceuticals.

May 18, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 1, 2023)

Vertex Pharmaceuticals reported first quarter 2023 results on May 1, 2023, with product revenue of $2.37 billion, up 13% year over year, driven mainly by strong international uptake of TRIKAFTA/KAFTRIO and continued U.S. performance of TRIKAFTA. U.S. product revenue rose 3% to $1.40 billion, while ex-U.S. revenue grew 33% to $971 million. Profitability declined: GAAP net income fell 8% to $699.8 million ($2.69 diluted EPS) and non-GAAP net income fell 12% to $794.0 million ($3.05 non-GAAP diluted EPS). The decline reflects a $347.1 million acquired IPR&D charge (versus $2.0 million a year earlier), higher clinical-stage R&D spending, and launch-related costs. Interest income rose sharply to $122.6 million from $1.6 million, partly offsetting these pressures. Management reiterated full-year 2023 guidance, including CF product revenue of $9.55 to $9.7 billion, combined non-GAAP R&D, acquired IPR&D and SG&A expenses of $3.9 to $4.0 billion, and a non-GAAP tax rate of 21% to 22%. The guidance includes an approximately 150-basis-point headwind from foreign currency. Cash, cash equivalents and marketable securities were $11.5 billion at quarter end, versus $10.9 billion at year end per the press release text, although the balance sheet in the exhibit shows $10.4 billion, a discrepancy investors should reconcile against the full filing. Operationally, the FDA approved TRIKAFTA for children aged 2 to 5, adding about 900 newly eligible patients, and Vertex completed the rolling U.S. BLA submissions for exa-cel in sickle cell disease and beta thalassemia, with Priority Review requested. Vertex also advanced its pipeline in type 1 diabetes, AAT deficiency and APOL1-mediated kidney disease, and made external investments including a $100 million upfront payment to CRISPR Therapeutics and roughly $225 million plus a $25 million equity investment in Entrada Therapeutics.

May 1, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 7, 2023)

Vertex Pharmaceuticals reported strong fourth-quarter and full-year 2022 results, with full-year product revenue of $8.93 billion, up 18% from 2021, driven mainly by rapid international uptake of TRIKAFTA/KAFTRIO and continued U.S. TRIKAFTA performance. GAAP net income rose 42% to $3.32 billion and non-GAAP net income rose 53% to $3.86 billion. The 2021 comparison was depressed by a one-time $900 million CRISPR payment, so much of the earnings improvement reflects lower acquired IPR&D rather than only operating growth. Fourth-quarter product revenue grew 11% to $2.30 billion, while fourth-quarter GAAP net income grew only 6%, reflecting higher R&D, launch costs and taxes. Management guided 2023 CF product revenue to $9.55–$9.7 billion and combined non-GAAP R&D, acquired IPR&D and SG&A expenses to $3.9–$4.0 billion, with a non-GAAP effective tax rate of 21–22%. The guidance includes an approximately 150-basis-point negative FX impact and roughly $300 million of upfront and milestone payments tied to existing collaborations and the anticipated Entrada Therapeutics deal. Cash and marketable securities reached $10.8 billion at year-end, and the board approved a new $3.0 billion share repurchase program with no expiration date. The company also outlined several potential near-term launches and regulatory milestones. These include exa-cel in sickle cell disease and beta thalassemia, where the EU and U.K. filings are validated and the U.S. rolling BLA is expected to be completed by end of Q1 2023. Pediatric TRIKAFTA/KAFTRIO (ages 2–5) has an FDA PDUFA date of April 28, 2023, and pediatric KALYDECO (infants from 1 month) has a PDUFA date of May 3, 2023. Pivotal Phase 3 work on VX-548 for acute pain continues, with completion expected in late 2023 or early 2024.

Feb 7, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Oct 27, 2022)

Vertex Pharmaceuticals (VRTX) reported third quarter 2022 results on October 27, 2022, delivering product revenue of $2.33 billion, up 18% year over year, driven mainly by strong international uptake of TRIKAFTA/KAFTRIO and steady U.S. TRIKAFTA performance. U.S. net product revenue rose 5% to $1.46 billion, while ex-U.S. revenue grew 46% to $879 million. GAAP net income increased 9% to $931 million ($3.59 diluted EPS), and non-GAAP net income rose 14% to $1.04 billion ($4.01 per diluted share). Note that starting in Q1 2022, Vertex no longer excludes upfront or milestone R&D charges from non-GAAP results, and 2021 comparatives were recast accordingly. Management raised full-year 2022 product revenue guidance to $8.8-$8.9 billion from $8.6-$8.8 billion, while leaving combined GAAP and non-GAAP R&D, acquired IPR&D and SG&A expense guidance and the non-GAAP tax rate guidance unchanged. Cash, cash equivalents and marketable securities reached $9.8 billion at quarter end, up about $2.2 billion year to date, despite income tax payments and the ViaCyte acquisition. Combined expenses rose as Vertex invested in mid- and late-stage programs and launch support. Pipeline progress is the other focus. Vertex plans to begin global regulatory submissions for exa-cel in sickle cell disease and beta thalassemia, with a U.S. BLA rolling submission starting in November 2022 and EU/UK filings in Q4 2022. The company also initiated a Phase 3 pivotal program for the NaV1.8 pain candidate VX-548 and advanced several other programs, including inaxaplin for APOL1-mediated kidney disease and the type 1 diabetes cell therapy VX-880. The filing itself is a routine earnings-release report furnished under Item 2.02, so the press release is not deemed filed under Section 18 of the Exchange Act.

Oct 27, 2022 8-K

Other EventsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 4, 2022)

Vertex Pharmaceuticals (VRTX) reported strong second-quarter 2022 results, with product revenues of $2.20 billion, up 22% from Q2 2021, driven mainly by TRIKAFTA/KAFTRIO uptake both in the U.S. and internationally. U.S. net product revenues rose 13% to $1.42 billion, while ex-U.S. revenues grew 46% to $781 million. GAAP net income was $810.5 million ($3.13 diluted EPS) versus $67.0 million a year earlier. The year-ago period was depressed by a one-time $900 million upfront payment to CRISPR Therapeutics, so the comparison flatters growth in net income and operating income. Cash, cash equivalents and marketable securities reached $9.3 billion, up about $1.7 billion since year-end 2021. Management raised full-year 2022 product revenue guidance to $8.6–$8.8 billion from $8.4–$8.6 billion. It also raised combined GAAP R&D, Acquired IPR&D and SG&A expense guidance to $3.48–$3.63 billion, reflecting pipeline advancement and business development activity. The non-GAAP expense guidance was raised to $3.0–$3.1 billion. Non-GAAP effective tax rate guidance is unchanged at 21% to 22%, and the GAAP effective tax rate is not guided. Beyond CF, the company highlighted progress across its pipeline, including exa-cel for sickle cell disease and beta thalassemia, inaxaplin for APOL1-mediated kidney disease (which received FDA Breakthrough Therapy designation), VX-548 for acute pain (also with Breakthrough designation), and VX-880 for type 1 diabetes. It also announced the pending $320 million ViaCyte acquisition, expected to close later in 2022. Investors should note that the company now excludes no R&D milestone charges from non-GAAP results, a definitional change applied starting Q1 2022 with prior periods recast.

Aug 4, 2022 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Jul 11, 2022)

On July 9, 2022, Vertex Pharmaceuticals (VRTX) entered into a Merger Agreement to acquire ViaCyte, Inc., a privately held biotechnology company developing stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D). Vertex will pay approximately $320 million in cash at closing, with a portion escrowed to cover ViaCyte equityholders' post-closing indemnification obligations. The deal is structured as a merger of Vertex's wholly-owned subsidiary into ViaCyte, with ViaCyte surviving as a wholly-owned Vertex subsidiary. ViaCyte's board has approved the transaction, and stockholders sufficient to approve the merger have delivered irrevocable written consents, so the remaining gating items are the expiration of the Hart-Scott-Rodino waiting period and the absence of a material adverse effect on ViaCyte. Strategically, the acquisition is aimed at accelerating Vertex's T1D program, centered on VX-880, an investigational allogeneic, fully differentiated, insulin-producing islet cell therapy that has shown proof of concept in an ongoing Phase 1/2 study. Vertex expects ViaCyte's additional human stem cell lines, differentiation intellectual property, GMP manufacturing facilities for cell-based therapies, and access to hypoimmune stem cell assets through ViaCyte's collaboration with CRISPR Therapeutics to strengthen its cell replacement efforts. Vertex intends to fund the purchase from cash on hand or other immediately available sources, and it expects the deal to close later in 2022. For investors, the transaction is modest in size relative to Vertex's scale, and the filing provides no revenue, earnings, or pro forma financial impact figures. The principal value driver is the potential to accelerate a pipeline asset outside Vertex's core cystic fibrosis franchise. Key risks flagged in the filing include regulatory clearance timing, the chance Vertex fails to realize the expected benefits, and the possibility that early, limited-patient clinical data for T1D programs do not translate into registration or further development.

Jul 11, 2022 8-K

Material AgreementsFinancial Events

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Jul 5, 2022)

Vertex Pharmaceuticals Incorporated (VRTX) has entered into a new $500 million senior unsecured revolving credit facility, the "2022 Credit Agreement", effective July 1, 2022. This facility matures on July 1, 2027, and allows for potential increases of an additional $500 million, subject to certain conditions. The proceeds are designated for general corporate purposes, providing Vertex with financial flexibility for its ongoing operations and strategic initiatives. This new credit agreement replaces the company's prior 2019 credit facility, which was terminated and fully repaid upon the establishment of the new agreement. The 2022 Credit Agreement includes provisions for borrowing in U.S. Dollars and certain non-U.S. Dollar alternative currencies, with interest rates tied to either a base rate or a SOFR-based rate, plus an applicable margin that fluctuates based on the Company's Consolidated Leverage Ratio or credit rating. The agreement also includes customary covenants and events of default, with a financial covenant requiring the maintenance of a Consolidated Leverage Ratio of 3.50 to 1.00, extendable to 4.00 to 1.00 following a material acquisition.

Jul 5, 2022 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (May 23, 2022)

Vertex Pharmaceuticals Incorporated (VRTX) announced on May 23, 2022, the acquisition of Catalyst Biosciences, Inc.'s complement portfolio and related intellectual property, including the drug candidate CB 2782-PEG. This strategic move signifies Vertex's continued investment in expanding its pipeline and exploring new therapeutic areas beyond its core focus. The acquisition was completed on May 19, 2022, with Vertex paying a total of $60 million in cash for the Transferred Assets. This expenditure is expected to be recognized as a GAAP and non-GAAP operating expense in the second quarter of 2022. Investors should monitor the integration of these assets and their potential contribution to Vertex's future growth.

May 23, 2022 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Shareholder Vote Results (May 18, 2022)

This 8-K filing details the results of Vertex Pharmaceuticals Incorporated's Annual Meeting of Shareholders held on May 18, 2022. The primary outcomes include the re-election of all eleven director nominees, the ratification of Ernst & Young LLP as the independent registered public accounting firm, and the approval of the company's 2021 executive compensation program on an advisory basis. Additionally, shareholders approved an amendment to increase the number of shares available under the 2013 Stock and Option Plan.

May 18, 2022 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 5, 2022)

Vertex Pharmaceuticals reported first quarter 2022 results on May 5, 2022, with product revenues of $2.10 billion, up 22% year over year. TRIKAFTA/KAFTRIO drove the growth, with TRIKAFTA/KAFTRIO revenue rising to $1.76 billion from $1.19 billion, while the older SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO franchises declined. GAAP net income was $762 million ($2.96 per diluted share, up 19%), and non-GAAP net income was $907 million ($3.52 per diluted share, up 18%). Vertex reiterated full-year 2022 product revenue guidance of $8.4 to $8.6 billion and ended the quarter with $8.2 billion in cash, cash equivalents and marketable securities. The most important accounting change is that, beginning in Q1 2022, Vertex no longer excludes R&D charges tied to upfront or contingent milestone payments from non-GAAP results. Prior-year 2021 non-GAAP figures were recast to match. The change is material: 2021 non-GAAP net income falls from $3,384 million to $2,513 million, and 2021 non-GAAP EPS falls from $13.02 to $9.67, largely because of the $900 million upfront payment to CRISPR Therapeutics in Q2 2021. Investors comparing non-GAAP figures across periods should use the recast numbers. The Q1 2022 non-GAAP comparison is not materially distorted, since Q1 2021 had only $0.7 million of such charges. The filing also flags a setback in the pipeline. The FDA placed the VX-880 type 1 diabetes program on clinical hold in the U.S. over insufficient information for dose escalation. Vertex is working with the agency to resolve the questions. Management reported positive proof-of-concept data across several programs, including VX-147 in APOL1-mediated kidney disease, which has entered pivotal development, and VX-548 in acute pain, which is slated to move into pivotal development in the second half of 2022.

May 5, 2022 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Jan 26, 2022)

Vertex Pharmaceuticals (VRTX) reported strong fourth quarter and full-year 2021 results, filed under Item 2.02 of Form 8-K on January 26, 2022. Full-year 2021 product revenues rose 22% to $7.57 billion, driven by the launch of KAFTRIO in Europe and other international markets and the continued uptake of TRIKAFTA in the U.S. Fourth-quarter product revenues grew 27% to $2.07 billion. Non-GAAP operating income rose 24% to $4.34 billion for the year, while GAAP operating income fell 3% to $2.78 billion, largely because of a $900 million upfront payment to CRISPR Therapeutics recorded as R&D expense. GAAP net income declined 14% to $2.34 billion for the year, while non-GAAP net income grew 24% to $3.38 billion. Diluted GAAP EPS was $9.01 and non-GAAP EPS was $13.02. For 2022, Vertex guided to product revenues of $8.4 to $8.6 billion, based mainly on continued TRIKAFTA growth in the U.S. and KAFTRIO outside the U.S. It also guided to combined non-GAAP R&D and SG&A expenses of $2.70 to $2.75 billion and a non-GAAP effective tax rate of 21% to 22%. Management highlighted several pipeline catalysts for 2022, including Phase 1/2 VX-880 type 1 diabetes data, pivotal development of VX-147 in APOL1-mediated kidney disease, Phase 2 acute pain data for VX-548, and regulatory filings for CTX001 in sickle cell disease and beta thalassemia in late 2022. Cash, cash equivalents and marketable securities ended the year at $7.5 billion, up about $0.9 billion year over year, after the $900 million CRISPR payment and share repurchases. Investors should note that the company's revenue growth remains concentrated in its CF franchise, particularly TRIKAFTA, so the 2022 outlook depends heavily on continued CF uptake and reimbursement expansion. The gap between GAAP and non-GAAP results is large, mainly because of collaboration-related expenses and stock-based compensation, so investors should weigh both measures. The filing also includes standard forward-looking statement cautions.

Jan 26, 2022 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Nov 2, 2021)

Vertex Pharmaceuticals (VRTX) reported third-quarter 2021 results on November 2, 2021, with product revenues of $1.98 billion, up 29% year over year, driven mainly by TRIKAFTA/KAFTRIO. U.S. product revenues rose 13% to $1.38 billion, while ex-U.S. revenues rose 92% to $601 million, reflecting the European KAFTRIO launch. GAAP net income was $852 million ($3.28 diluted EPS, up 30%), and non-GAAP net income was $926 million ($3.56 diluted EPS, up 35%). Management raised full-year 2021 product revenue guidance to $7.4–$7.5 billion from $7.2–$7.4 billion. Cash and marketable securities stood at $7.0 billion. The quarter's operating profile was solid but the nine-month picture is distorted by the $900 million upfront payment to CRISPR Therapeutics, which sits in R&D and drives nine-month GAAP net income down to about $1.57 billion from $2.11 billion a year earlier. Combined GAAP R&D and SG&A guidance is unchanged at $3.8–$3.95 billion, with the gap to non-GAAP guidance mainly reflecting $1.0–$1.1 billion of business development payments and $415–$445 million of stock-based compensation. Investors should watch the cadence of further business development spending, since it can materially swing GAAP results. Pipeline catalysts were highlighted, including early Phase 1/2 data for VX-880 in type 1 diabetes, VX-147 Phase 2 proof-of-concept results expected in Q4 2021, and VX-548 acute pain Phase 2 data expected in Q1 2022. Pivotal CTX001 submissions are planned for late 2022. The press release is furnished under Item 2.02 and is not deemed filed under Section 18 of the Exchange Act.

Nov 2, 2021 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Jul 29, 2021)

Vertex Pharmaceuticals (VRTX) reported second-quarter 2021 results on July 29, 2021, with product revenues of $1.79 billion, up 18% year over year, driven by strong TRIKAFTA/KAFTRIO uptake. U.S. product revenues rose 4% to $1.26 billion, while ex-U.S. revenues jumped 71% to $536 million, largely on KAFTRIO launches in Europe. Non-GAAP operating income grew 18% to $1.03 billion and non-GAAP diluted EPS rose 19% to $3.11. GAAP results were sharply weaker, with an operating loss of $38 million and diluted EPS of $0.26 (down 92%). The decline reflects a $900 million upfront payment to CRISPR Therapeutics under the amended CTX001 collaboration, which was recorded as R&D expense. Investors should view the non-GAAP figures as the cleaner read on operating performance, while recognizing that the CRISPR payment is a real cash outlay that reduced cash, which ended the quarter at $6.71 billion in cash and marketable securities. Management raised full-year 2021 product revenue guidance to $7.2–$7.4 billion from $6.7–$6.9 billion, citing strong year-to-date performance and new reimbursement agreements. Pipeline catalysts were also highlighted, including planned Phase 3 starts for a next-in-class CF triple combination in 2H 2021, target enrollment for CTX001 studies in 3Q 2021, and a VX-548 acute pain bunionectomy trial with data expected by early 2022.

Jul 29, 2021 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Jun 24, 2021)

Vertex Pharmaceuticals Incorporated (VRTX) announced on June 24, 2021, that its Board of Directors has authorized a significant share repurchase program. This program allows for the repurchase of up to $1.5 billion of the company's common stock, with the program set to conclude by December 31, 2022. This strategic move signals management's confidence in the company's financial health and future prospects. The repurchases can be executed through various methods, including open market transactions and privately negotiated deals, offering flexibility in managing the program based on market conditions and other investment considerations. Investors should view this as a potential indicator of undervaluation or a commitment to returning capital to shareholders.

Jun 24, 2021 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Shareholder Vote Results (May 19, 2021)

Vertex Pharmaceuticals Incorporated (VRTX) held its annual shareholder meeting on May 19, 2021, where key corporate governance matters were voted upon. The primary outcomes of the meeting indicate strong shareholder support for the company's leadership and existing practices. All nominated directors were overwhelmingly elected, reflecting confidence in the board's stewardship. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, and approved, on an advisory basis, the 2020 executive compensation program. Of particular note for investors, the results demonstrate a high degree of alignment between management and shareholders on critical governance issues. The re-election of all directors with substantial 'for' votes and a significant majority in favor of the executive compensation plan suggest a stable and supportive shareholder base. The withdrawal of two shareholder proposals also implies either resolution of the underlying issues or a lack of broad support for their advancement at this time.

May 19, 2021 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Apr 29, 2021)

Vertex Pharmaceuticals reported first-quarter 2021 results on April 29, 2021, with product revenues of $1.72 billion, up 14% year over year, driven mainly by uptake of KAFTRIO in Europe and continued growth of TRIKAFTA in the U.S. U.S. net product revenues rose 6% to $1.25 billion, while ex-U.S. revenues rose 43% to $470 million. GAAP operating income grew 23% to $888 million and GAAP diluted EPS rose 9% to $2.49. Non-GAAP diluted EPS rose 16% to $2.98. Cash, cash equivalents and marketable securities reached $6.9 billion at quarter-end, up $265 million from year-end 2020, even after share repurchases. The most significant forward-looking item is the amended CRISPR Therapeutics collaboration for CTX001 (beta thalassemia and sickle cell disease). Vertex will lead worldwide development and commercialization and receive 60% of program economics, while CRISPR receives 40%. CRISPR gets a $900 million upfront payment at closing, plus up to $200 million upon regulatory approval. Vertex raised its full-year 2021 GAAP R&D and SG&A expense guidance by $900 million to $3.8–3.95 billion, but reiterated its product revenue guidance of $6.7–6.9 billion and its non-GAAP expense and tax guidance. Investors should expect a sizable GAAP expense step-up in 2021 that is largely non-cash or tied to the collaboration, while the company's core revenue outlook is unchanged. Pipeline news included VX-548 advancing toward Phase 2 in acute pain, the start of a Phase 1/2 trial for VX-880 in type 1 diabetes, and completed enrollment and dosing in a Phase 2 study of the AAT corrector VX-864. Several Phase 2 readouts are expected in 2021, including VX-864 results in Q2 and VX-147 in APOL1-mediated FSGS in the second half. Also noted: the company expects a larger share of its tax provision to be cash taxes beginning in 2021 as its NOLs are used up.

Apr 29, 2021 8-K

Material Agreements

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Apr 20, 2021)

Vertex Pharmaceuticals (VRTX) has entered into an Amended and Restated Joint Development and Commercialization Agreement (A&R JDCA) with CRISPR Therapeutics AG, significantly altering the terms of their collaboration concerning CTX001TM and other product candidates. Under the new agreement, Vertex will assume leadership for global development, manufacturing, and commercialization of CTX001, with support from CRISPR. This shift in responsibility is accompanied by a revised financial structure, including an upfront payment of $900.0 million from Vertex to CRISPR and a future milestone payment of $200.0 million upon the first marketing approval of CTX001. The profit and loss sharing for CTX001 will also be adjusted, moving from an equal split to a 60/40 allocation in favor of Vertex starting from July 1, 2021, while other product candidates will maintain an equal profit and loss sharing. The A&R JDCA also introduces new governance structures, including a joint oversight committee and a transition committee, replacing previous working groups. The agreement allows for opt-out rights for either party on a candidate-by-candidate basis, with the opting-out party receiving royalties on net sales instead of sharing in profits and losses. Vertex retains the right to terminate the agreement for convenience. This revised agreement is a significant development for both companies, streamlining operations and adjusting financial contributions as they advance the development of potentially groundbreaking therapies.

Apr 20, 2021 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 1, 2021)

Vertex Pharmaceuticals (VRTX) reported full-year and fourth-quarter 2020 results in a press release furnished under Item 2.02 of this 8-K. Full-year 2020 GAAP product revenues were $6.20 billion, up 49% from $4.16 billion in 2019, and non-GAAP product revenues were also $6.20 billion, up 55% from $4.01 billion. Growth was driven primarily by uptake of TRIKAFTA/KAFTRIO in the U.S. and Europe and by reimbursement wins in other markets. GAAP net income rose 130% to $2.71 billion ($10.29 diluted EPS), while non-GAAP net income rose 96% to $2.72 billion ($10.32 non-GAAP diluted EPS). Fourth-quarter GAAP product revenues were $1.63 billion, up 15% year over year (29% non-GAAP), and cash, cash equivalents and marketable securities reached $6.7 billion at year end, up about $2.9 billion. Management guided to full-year 2021 product revenues of $6.7 to $6.9 billion, implying roughly 8% to 11% growth over 2020. Guidance also calls for combined non-GAAP R&D and SG&A expenses of $2.25 to $2.3 billion, a non-GAAP effective tax rate of 21% to 22%, and combined GAAP R&D and SG&A expenses of $2.9 to $3.05 billion. The gap between GAAP and non-GAAP expense guidance is mainly stock-based compensation and collaboration-related R&D. The company also flagged that its tax provision will shift toward a larger cash component now that it has used substantially all of its federal NOLs in 2020. Beyond the financials, the release updated the CF franchise, including FDA expansion of TRIKAFTA eligibility to ages 12 and older and a sNDA for ages 6 to 11 with a June 8, 2021 PDUFA date. Pipeline milestones include Phase 2 data for VX-864 (AAT deficiency) in the first half of 2021, Phase 2 data for VX-147 (APOL1-mediated FSGS) in 2021, and planned Phase 1/2 initiation for VX-880 (type 1 diabetes) in the first half of 2021. The company also reported ongoing CRISPR-partnered gene editing trials in sickle cell disease and beta thalassemia, with enrollment completion expected in 2021.

Feb 1, 2021 8-K